NEUROTROPE: EXCEPTIONAL PROMISE IN THE DIAGNOSIS AND TREATMENT OF EARLY STAGE ALZHEIMER’S DISEASE ****
MY DEAR FRIEND AND E-PAL DR. JOHN ABELES IS FOUNDER AND CHAIRMAN OF NEUROTROPE, INC. RSK
www.neurotropebioscience.com
Neurotrope BioScience is collaborating with the Blanchette Rockefeller Neuroscience Institute (BRNI) to advance novel diagnostic and therapeutic technologies developed at BRNI that have shown exceptional promise in both preclinical and clinical models of Alzheimer’s Disease. The commercial introduction of a new, non-invasive diagnostic test for early stage Alzheimer’s Disease is the first milestone this collaboration seeks to achieve. Following this, the BRNI-Neurotrope BioScience team plans on initiating several Phase 2 clinical trials in this disease with novel drug prototypes discovered at BRNI.
The research team at BRNI has pioneered a new approach to treat neurodegenerative disease through the activation of protein kinase C-epsilon (PKCε). While the inhibition of PKC has previously been explored in clinical studies for the treatment of cancer, BRNI has discovered the selective activation of this enzyme is effective in treating memory and cognition disorders stemming from neurodegenerative disease. This approach exploits a complex pathway of biochemical events in the neuron that seem to be centrally orchestrated by PKCε. The changes mediated by PKCε effectively converge in reversing the neuronal damage and loss central to the pathogenic process in Alzheimer’s Disease.
About Neurotrope
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer’s Disease and a drug candidate called bryostatin for the treatment of Alzheimer’s Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute (“BRNI”) and its affiliates, for therapeutic or diagnostic applications for Alzheimer’s Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer’s Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer’s Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the “blood-brain-barrier,” and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.
Please visit www.neutropebiosciences.com for further information.
Comments are closed.
